Caris Life Sciences

Caris Detect is a blood test that looks for signs of early-stage cancer. When cancer is growing in your body, it leaves tiny clues in your blood, and Caris Detect can find them. It can spot these clues even when the cancer is very small and just starting to grow and even more importantly, before it spreads. This is important because the earlier cancer is found, the better the chance of beating it. Learn more and get the test at CarisDetect.com

Caris molecular profiling helps Dr. Christopher Vaughn uncover possible mutations within a patient’s tumor and identify potential clinical trial opportunities. These insights help guide more informed, personalized treatment decisions. Learn how molecular profiling shapes his approach to care: ow.ly/hTG850Z9wp9

Caris Detect™ is the blood test designed to catch cancer in the early stages of the disease, including breast cancer before a physical exam may find it. Caris Detect looks for tiny signals of all genetic material from cancer instead of just a limited portion of DNA to find cancer signals in early stage, when treatment is most effective. 55+ cancers. One blood draw. Breast cancer included. Know in early stage. Learn more and get the test at: CarisDetect.com

The enhanced Caris Assure® test adds RNA-based fusion detection through a dedicated whole transcriptome workflow — providing insights that DNA profiling alone can miss. See what’s new. ow.ly/R1zU50ZYfSm

Could multimodal AI help identify which patients with early-stage HR+ breast cancer may benefit from extended endocrine therapy? In an NSABP B-42 cohort, significant benefit was observed in about one-quarter of patients the models classified as both high risk for late distant recurrence and likely to benefit from extended therapy. #ESMOAI26. ow.ly/Rqh15101alG

Can AI help characterize capecitabine response in ER+ breast cancer? The Caris-led CapeAI study used clinico-genomic and next-generation sequencing (NGS) features to classify response to this common chemotherapy. In an independent validation cohort, patients predicted to respond had longer progression-free survival; in a Caris cohort, predicted responders had longer time to next treatment and longer overall survival. #ESMOAI26 ow.ly/BLHa5101alF

Our team is waiting to chat with you at booth 1021. Take the opportunity to network with Caris at ESMO 2026 (@myESMO). ow.ly/EBuM510196W

MI Cancer Seek® provides molecular profiling for solid tumors with FDA-approved CDx indications. Available for both adult and pediatric patients (ages 1+). Learn more & view important product info: bit.ly/4lyGNTR

Fragmented genetic testing can limit insight into myeloid malignancies. Caris ChromoSeq consolidates multiple methods into one Whole Genome Sequencing (WGS) assay, delivering a comprehensive view to support diagnosis and risk stratification. Learn more: bit.ly/4ufznZw

Join Caris and other leaders from the global oncology community at ESMO 2026. Discover the latest advancements in precision oncology, connect with our team at booth #1021 and learn how deeper molecular insights are helping support more informed treatment decisions. Schedule a meeting: ow.ly/efEV50ZUEQN #ESMOAI26

Your breast cancer journey is personal. Caris MI Clarity™ may help support a more informed conversation about your care plan by providing additional insight into your risk of breast cancer recurrence over time. Talk with your healthcare provider about MI Clarity. bit.ly/4n8Jb5f

At Caris, we’re committed to supporting patients throughout their cancer journey. In recognition of #BreastCancerAwarenessMonth, Dr. @GeorgeSledge51 shares the top 3 things to do when diagnosed with breast cancer. Watch and learn more: bit.ly/44yVbFv

When treatment decisions can depend on a single molecular finding, confidence and accuracy matter. The goal is not simply to detect more signals — it's to deliver clinically actionable findings that can help physicians guide treatment decisions with confidence. Learn more about Caris Assure®: ow.ly/p10r50ZBEIs

Ball speed. Launch angle. Spin rate. In golf, AI has analyzed millions of swings to help players like three-time major champion Jordan Spieth sharpen their game. If AI can analyze every detail of a swing, shouldn’t it also analyze your health? With Caris Detect™, it does. This multi-cancer early detection test analyzes your entire genome and transcriptome from a single blood draw, using AI trained on more than 50 billion molecular markers from over 1 million patient cases to help find cancer early when treatment is most effective. That can make all the difference. Because some things in life aren’t a game. Know early. Get the test at CarisDetect.com.

Collaboration with Jordan Spieth, three-time major champion professional golfer. Three-time major champion Jordan Spieth sits down with Caris Founder, Chairman and CEO David Dean Halbert to discuss how AI is sharpening athletic performance and advancing early-stage cancer detection. Get the test at CarisDetect.com.

Three-time major champion Jordan Spieth knows golf runs on data: ball speed, launch angle, spin rate, and AI that has analyzed millions of swings. So why not use that same intelligence for something that means everything, your health? Caris Detect™ is a multi-cancer early detection test that analyzes your entire genome and transcriptome from a single blood draw. Powered by AI trained on more than 50 billion molecular markers from over 1 million patient cases; it helps find cancer early when treatment is most effective. Some things in life aren’t a game. Stop waiting. Know early. Get the test at CarisDetect.com.